Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.